GlassScriptPhysician profile
Steven N Mandrea
NPI 1386663631
$22,723.94
in general payments reported to CMS, 2019-2025
35 companies · $4,960 in 2025
The $4,960 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $196 · 2021: $934 · 2022: $3,879 · 2023: $4,414 · 2024: $7,270 · 2025: $4,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,738 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,583.90 |
| Consulting Fee | $1,737.50 |
| Education | $322.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,243.90 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $4,072.48 | 2019-2025 | |
| Epi Health, LLC | $1,529.65 | 2022 | |
| Lilly USA, LLC | $1,166.95 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,165.02 | 2019-2025 | Ilumya, Winlevi |
| Incyte Corporation | $1,058.91 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,013.34 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $909.85 | 2021-2025 | |
| Ucb, INC. | $888.51 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $780.02 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $713.41 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $700.46 | 2019-2025 | Aklief, Nemluvio, Oracea |
| E.R. Squibb & Sons, L.L.C. | $698.26 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $620.95 | 2020-2025 | |
| Biofrontera INC. | $557.06 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $509.55 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $448.96 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $377.97 | 2023-2025 | Zoryve |
| Strata Skin Sciences, INC. | $259.19 | 2019-2025 | Xtrac |
| Janssen Scientific Affairs, LLC | $234.46 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.79 | 2022-2025 | Cyltezo, Spevigo |
| Organon LLC | $151.63 | 2025 | Vtama, Hadlima |
| Merz North America, INC. | $78.32 | 2023 | Xeomin |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Mayne Pharma Commercial LLC | $57.11 | 2022-2025 | |
| Allergan, INC. | $52.18 | 2019-2021 | |
| Almirall LLC | $44.16 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $34.96 | 2023-2024 | Idacio |
| Genentech USA, INC. | $25.29 | 2023 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.43 | 2023 | Siliq |
| Solta Medical, A Division of Bausch Health US, LLC | $20.14 | 2020 | |
| Mission Pharmacal Company | $19.38 | 2019 | |
| Smith+Nephew, INC. | $17.13 | 2025 | Grafix Pl |
| Dusa Pharmaceuticals, INC. | $11.77 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mandrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.